Synergistic and additive effects of rifampicin, moxifloxacin, ethambutol, and azithromycin against M. simiae clinical isolates
Abstract
Pulmonary disease caused by Mycobacterium simiae is challenging to treat due to intrinsic resistance and limited guidelines. We assessed synergy among rifampicin, moxifloxacin, ethambutol, and azithromycin using the checkerboard method. Synergy (FICI = 0.5) was found only for the moxifloxacin-ethambutol combination in 63% of 27 clinical isolates, with the remainder showing additive effects. No synergy was observed for rifampicin or azithromycin. These findings suggest potential therapeutic benefit for the moxifloxacin-ethambutol combination, even in non-susceptible isolates, supporting reconsideration of ethambutol in treatment regimens. Clinical studies are needed to validate the observed in vitro synergy.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.